Physician profile
Timothy H Eidson
NPI 1164418448
$885.73
in general payments reported to CMS, 2019-2025
15 companies · $49.15 in 2025
The $49.15 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $97.52 · 2021: $225 · 2022: $214 · 2023: $92.34 · 2024: $61.10 · 2025: $49.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $202.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $162.43 | 2019-2025 | |
| Tris Pharma INC | $149.51 | 2019-2022 | |
| Sanofi Pasteur INC. | $129.99 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $93.36 | 2019-2024 | M-M-R II, Gardasil 9, Vaxelis |
| Seqirus USA INC | $77.60 | 2021-2023 | Flucelvax Quadrivalent |
| Glaxosmithkline, LLC. | $58.55 | 2020-2023 | Pediarix, Bexsero |
| Ironshore Pharmaceuticals INC. | $39.67 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $38.50 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $22.82 | 2023 | Ycanth |
| Astrazeneca Pharmaceuticals Lp | $22.55 | 2024 | Flumist Quadrivalent |
| Sobi, INC | $22.09 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.01 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.31 | 2019 | |
| Phadia US INC. | $16.99 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Eidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.